Biotech

Venture capital funding for biotech companies have reached record levels. Getting positive investor attention is key to helping provide long-term, necessary funding to help deliver important and innovative medicines to patients.

However, with increased visibility and scrutiny, creating value is not guaranteed. The increasingly complex value chain system, including the pharmacoeconomic aspect can be a challenge for early biotech companies launching their first product.

ACMA helps biotech companies across the entire value chain, from early-stage companies getting initial funding to established companies launching into international markets.

We also drive transformations by bringing together the capabilities needed to help organizations grow and thrive in the digital age such as training, certification, accreditation, digital support and advisory services.